Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Mektovi (binimetinib)
i
Other names:
MEK162, ARRY-438162, ARRY-162, ONO-7703, PF06811462, PF 06811462, PF-06811462, W-0074, W 0074, W0074, ARRY162, ARRY 162, ARRY438162, ARRY 438162, MEK-162, MEK 162, ONO7703, ONO 7703
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(68)
News
Trials
Company:
Medison, Ono Pharma, Pfizer, Pierre Fabre
Drug class:
MEK inhibitor
Related drugs:
‹
trametinib (330)
selumetinib (106)
mirdametinib (30)
avutometinib (27)
BAY86-9766 (16)
CI-1040 (15)
tunlametinib (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
NFX-179 (0)
PF-07799544 (0)
WX-554 (0)
SNR1611 (0)
trametinib (330)
selumetinib (106)
mirdametinib (30)
avutometinib (27)
BAY86-9766 (16)
CI-1040 (15)
tunlametinib (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
NFX-179 (0)
PF-07799544 (0)
WX-554 (0)
SNR1611 (0)
›
Associations
(68)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Non Small Cell Lung Cancer
BRAF V600E
Non Small Cell Lung Cancer
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
NRAS mutation
Melanoma
NRAS mutation
Melanoma
binimetinib
Sensitive: A2 - Guideline
binimetinib
Sensitive
:
A2
binimetinib
Sensitive: A2 - Guideline
binimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
BRAF V600E
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
BRAF V600K
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
NRAS mutation
Cutaneous Melanoma
NRAS mutation
Cutaneous Melanoma
binimetinib
Sensitive: A2 - Guideline
binimetinib
Sensitive
:
A2
binimetinib
Sensitive: A2 - Guideline
binimetinib
Sensitive
:
A2
SDHB deletion
Gastrointestinal Stromal Tumor
SDHB deletion
Gastrointestinal Stromal Tumor
binimetinib + YD312
Sensitive: A2 - Guideline
binimetinib + YD312
Sensitive
:
A2
binimetinib + YD312
Sensitive: A2 - Guideline
binimetinib + YD312
Sensitive
:
A2
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
binimetinib + encorafenib
Sensitive: B - Late Trials
binimetinib + encorafenib
Sensitive
:
B
binimetinib + encorafenib
Sensitive: B - Late Trials
binimetinib + encorafenib
Sensitive
:
B
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.